Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances

Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances

Therapeutic development for metabolic-dysfunction-associated steatohepatitis (MASH) trails behind the success seen in hepatitis C virus (HCV) management. HCV, characterized by a viral etiology, benefits from direct-acting antivirals (DAAs) targeting viral proteins, achieving cure rates exceeding 90%...

Full description

Saved in:
Bibliographic Details
Main Authors: Caesar Ferrari, Bilal Ashraf, Zainab Saeed, Micheal Tadros
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Gastroenterology Insights
Subjects:
metabolic-dysfunction-associated fatty liver disease (MAFLD)
metabolic-dysfunction-associated steatohepatitis (MASH)
hepatitis C
direct-acting antivirals (DAAs)
liver fibrosis
non-invasive diagnostics
Online Access:https://www.mdpi.com/2036-7422/15/4/66
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2036-7422/15/4/66

Similar Items